Contineum Therapeutics, Inc. Class A Common Stock (CTNM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a cash flow conversion efficiency ratio of -0.065x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.27 Million) by net assets ($250.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Contineum Therapeutics, Inc. Class A Com liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Contineum Therapeutics, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Contineum Therapeutics, Inc. Class A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samse SA
PA:SAMS
|
0.105x |
|
Star Gas Partners LP
NYSE:SGU
|
0.046x |
|
Shenzhen TVT Digital Technology Co Ltd
SHE:002835
|
0.031x |
|
Shanghai W Ibeda High Tech Group Co Ltd
SHG:688071
|
0.015x |
|
Development Investment Construction JSC
VN:DIG
|
0.114x |
|
Cub Elecparts Inc
TW:2231
|
0.005x |
|
Hana Tour
KO:039130
|
0.120x |
|
Metrics Income Opportunities Trust
AU:MOT
|
0.041x |
Annual Cash Flow Conversion Efficiency for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see CTNM market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $260.99 Million | $-55.31 Million | -0.212x | -27.80% |
| 2024-12-31 | $198.07 Million | $-32.84 Million | -0.166x | +41.78% |
| 2023-12-31 | $-67.94 Million | $19.35 Million | -0.285x | +44.41% |
| 2022-12-31 | $39.27 Million | $-20.12 Million | -0.512x | -20.14% |
| 2021-12-31 | $61.59 Million | $-26.27 Million | -0.426x | -- |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibr… Read more